Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$54.18 USD
+0.40 (0.74%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $54.14 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CYTK 54.18 +0.40(0.74%)
Will CYTK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTK
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
Other News for CYTK
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells Shares
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Buy Rating Affirmed: Cytokinetics’ Aficamten Shows Strong Commercial Promise in oHCM Treatment
Cytokinetics price target lowered by $12 at JPMorgan, here's why
Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)